Crossmark

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab

Crossref DOI link: https://doi.org/10.1007/s10147-018-1250-2

Published Online: 2018-02-13

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakaya, Aya http://orcid.org/0000-0001-8365-3987
Kurata, Takayasu

Yoshioka, Hiroshige

Takeyasu, Yuki

Niki, Maiko

Kibata, Kayoko

Satsutani, Naoko

Ogata, Makoto

Miyara, Takayuki

Nomura, Shosaku
License Information

Text and Data Mining valid from 2018-02-13
More Information

Article History

Received: 22 October 2017

Accepted: 7 February 2018

First Online: 13 February 2018

Compliance with ethical standards

:

: T. Kurata received honoraria from Ono Pharmaceutical and Bristol-Myers Squibb. The other authors disclosed no potential conflicts of interest.